ImmVirx Pty Ltd
ImmVirX is a clinical stage oncology company developing receptor targeted oncolytic RNA immunotherapies to enable powerful and durable responses in the most globally prevalent cancers with high unmet need. The company harnesses the power of viruses to infect and kill cancer cells, inducing systemic anti-tumour immune responses, and aims to increase the effectiveness of current therapies such as immune checkpoint inhibitors and CAR-T cells in treating high unmet need cancers including colorectal, gastric, hepatocellular, ovarian, pancreatic, and liver cancers.
Industries
Nr. of Employees
small (1-50)
ImmVirx Pty Ltd
Level 2, HMRI Building Kookaburra Circuit New Lambton Heights NSW 2305
Products
Lead oncolytic RNA virus candidate (clinical-stage)
Investigational receptor-targeted oncolytic RNA virus in clinical development for treatment of colorectal, gastric and ovarian cancers; administered intratumorally with development plans for combination with systemic PD-1 inhibitors.
Preclinical oncolytic RNA virus pipeline
Additional RNA virus candidates in preclinical development, including programs aimed at expanding indications to additional tumour types such as late-stage lung cancer.
Lead oncolytic RNA virus candidate (clinical-stage)
Investigational receptor-targeted oncolytic RNA virus in clinical development for treatment of colorectal, gastric and ovarian cancers; administered intratumorally with development plans for combination with systemic PD-1 inhibitors.
Preclinical oncolytic RNA virus pipeline
Additional RNA virus candidates in preclinical development, including programs aimed at expanding indications to additional tumour types such as late-stage lung cancer.
Services
End-to-end discovery and preclinical development using a bioselection approach to generate RNA virus candidates that target tumour-expressed receptors.
Design and conduct of multi-centre Phase 1a/1b studies with dose-escalation, cohort expansion and combination cohorts to assess safety, tolerability and exploratory biomarkers.
Structuring and executing collaborations that provide clinical drug supply for combination studies and coordinate joint clinical development activities with industry partners.
Pilot production, technology transfer to third-party manufacturers, scale-up planning and oversight of fill/finish processes for clinical-grade material.
In-house and partnered preclinical programs including toxicology and efficacy studies to support regulatory submissions and clinical entry.
End-to-end discovery and preclinical development using a bioselection approach to generate RNA virus candidates that target tumour-expressed receptors.
Design and conduct of multi-centre Phase 1a/1b studies with dose-escalation, cohort expansion and combination cohorts to assess safety, tolerability and exploratory biomarkers.
Structuring and executing collaborations that provide clinical drug supply for combination studies and coordinate joint clinical development activities with industry partners.
Pilot production, technology transfer to third-party manufacturers, scale-up planning and oversight of fill/finish processes for clinical-grade material.
In-house and partnered preclinical programs including toxicology and efficacy studies to support regulatory submissions and clinical entry.
Expertise Areas
- Oncolytic virotherapy development
- Early-phase clinical trial management (Phase 1a/1b)
- Preclinical in vivo efficacy and toxicology
- Biomanufacturing scale-up and technical transfer
Key Technologies
- Oncolytic RNA virus engineering
- Receptor-targeted bioselection
- In vivo xenograft models
- Intratumoral and intravenous delivery techniques
News & Updates
ImmVirX presented clinical and preclinical updates at the ESMO Congress in Berlin, highlighting its novel immunotherapies targeting prevalent cancers.
The company showcased progress in its oncolytic immunotherapies at the AACR Annual Meeting.
ImmVirX and Innovent announced an expansion of their collaboration to evaluate IVX037 with the checkpoint inhibitor TYVYT® in liver cancer.
The company announced the successful upsizing of its Series A funding to $25 million to support clinical development.
ImmVirX secured $15 million in Series B funding led by OneVentures to advance its oncolytic virus programs.
The company received a tax refund of $3.77 million from the Australian government to support its R&D activities.
ImmVirX presented clinical and preclinical updates at the ESMO Congress in Berlin, highlighting its novel immunotherapies targeting prevalent cancers.
The company showcased progress in its oncolytic immunotherapies at the AACR Annual Meeting.
ImmVirX and Innovent announced an expansion of their collaboration to evaluate IVX037 with the checkpoint inhibitor TYVYT® in liver cancer.
The company announced the successful upsizing of its Series A funding to $25 million to support clinical development.
ImmVirX secured $15 million in Series B funding led by OneVentures to advance its oncolytic virus programs.
The company received a tax refund of $3.77 million from the Australian government to support its R&D activities.